What triggered the TBPH analyst rating downgrade?

Oppenheimer cited negative Phase 3 trial results when it downgraded TBPH from Outperform to Perform on March 05, 2026. The firm flagged weaker near-term commercial prospects tied to the clinical readout.

Did Oppenheimer set a new TBPH price target with the downgrade?

Oppenheimer’s published note did not include a new TBPH price target on March 05, 2026. The downgrade focused on clinical risk and near-term outlook rather than a revised numeric target.

How should investors react to the TBPH downgrade?

Investors should reassess position size and risk tolerance after the TBPH downgrade. Short-term traders may reduce exposure, while long-term holders should wait for follow-up data or company guidance before changing core positions.

How significant is this single downgrade for overall analyst consensus on TBPH?

A single downgrade from Oppenheimer matters because it’s a notable firm, but it does not alone redefine consensus. Future analyst moves and clinical updates will determine whether sentiment shifts broadly.

Analyst Ratings

Oppenheimer Downgrades Theravance Biopharma (TBPH) to Perform, March 05 2026

ByHuzaifa Zahoor March 6, 2026

Oppenheimer downgraded Theravance Biopharma, Inc. (TBPH) from Outperform → Perform on March 05, 2026. This TBPH analyst rating change came after the company reported negative Phase 3 trial results, a central factor cited by the firm. The move trimmed near-term enthusiasm and corresponded with a reported intraday price change of -0.51% (-$0.07). Investors should note this shift from a primary analyst at Oppenheimer, as it changes risk expectations and trading sentiment for TBPH.